Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52‐week results from a double‐blind phase 3b trial (CLARITY)

BACKGROUND: Secukinumab demonstrated superior efficacy over ustekinumab in the treatment of moderate to severe plaque psoriasis over 16 weeks in the CLARITY study and over 52 weeks in the CLEAR study. OBJECTIVE: To compare the efficacy and safety of secukinumab vs. ustekinumab over 52 weeks in CLARI...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Eur Acad Dermatol Venereol
Hlavní autoři: Bagel, J., Blauvelt, A., Nia, J., Hashim, P., Patekar, M., de Vera, A., Ahmad, K., Paguet, B., Xia, S., Muscianisi, E., Lebwohl, M.
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2020
Témata:
Psoriasis
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7818402/
https://ncbi.nlm.nih.gov/pubmed/32365251
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jdv.16558
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky